<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00285402</url>
  </required_header>
  <id_info>
    <org_study_id>ARPH-Cl-03</org_study_id>
    <secondary_id>Eudract no: 2005-003349-15</secondary_id>
    <nct_id>NCT00285402</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine</brief_title>
  <official_title>Intranasal AST-726 Treatment for Prophylaxis of Migraine: A Placebo-Controlled Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ariston Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ariston Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this migraine prevention study is to evaluate the efficacy and safety of
      AST-726 in moderate to severe migraine patients at one of two doses compared to placebo and
      compared to a baseline period as measured by a reduction in the number of migraine days.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Migraine patients may experience repeated migraine attacks, lasting from four hours to three
      days or more. Each attack is characterized by severe pain, typically on one side of the head
      and often involves a number of other symptoms, including pain with a pulsating or throbbing
      quality, nausea or vomiting, sensitivity to light and sound, visual disturbances or aura.
      Currently the management of migraine may be either acute treatment or prophylaxis. Acute
      migraine treatment aims at aborting or reversing already present migraine symptoms with acute
      administration of medicine such as with triptans, whereas migraine prophylaxis aims to reduce
      the frequency and severity of migraine attacks over time through chronic medication.

      The overall protocol design and outcome measurements of this study follow the guidelines and
      durations recommended by the International Headache Society for prophylaxis studies of
      migraine medications.

      The study ARPH-CL-03 is a multicenter, randomized, double-blind, three parallel group design
      with moderate to severe migraine patients to assess the ability of daily administration of
      AST-726 at one of two doses to reduce the number of headache days in a 4 week period more
      than in patients that receive a placebo. AST-726 and the placebo will be self-administered by
      intranasal spray daily for 12 weeks. Among other efficacy and safety assessments, patients
      will have be asked to collect information on a daily migraine diary.

      Patients will be instructed on the allowed use of acute migraine medications during this
      study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2007</start_date>
  <completion_date type="Anticipated">June 2008</completion_date>
  <primary_completion_date type="Anticipated">June 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome variable will be change in number of migraine headache days during standardized 30-day observation periods during treatment period and baseline period. The number of headache days reported in the patient diary will be standardized.</measure>
    <time_frame>30 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 Number of subjects that respond with at least a 50% decrease in migraine days in each given 4-week Treatment Period</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2 The number of migraine headache attacks in each treatment period</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">198</enrollment>
  <condition>Migraine</condition>
  <condition>Migraine Headache</condition>
  <condition>Migraine Disorders</condition>
  <condition>Migraine With Aura</condition>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-726 Low dose</intervention_name>
    <arm_group_label>A</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-726 High dose</intervention_name>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AST-726 Placebo</intervention_name>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Primary Inclusion Criteria:

          1. Has migraine headaches with or without aura according to International Headache
             Society guidelines (Committee, 2004).

          2. Has had migraines for at least 6 months prior to study enrollment period.

          3. Migraines began before age 50.

          4. Has 2 to 10 attacks per month and greater than or equal to 3 migraine days per month
             in the last 3 months prior to study enrollment.

          5. Has 2 to 10 attacks in 30 days during the Baseline Period.

        Additional inclusion criteria in protocol

        Primary Exclusion Criteria:

          1. Has headache equal to or greater than 18 days per month.

          2. Has used migraine medications (e.g., topiramate, beta-blockers) for prophylactic use
             within 60 days prior to study enrollment.

          3. Has excessive use of acute migraine medications (e.g., triptans, dihydroergotamine
             [DHE]) greater than 15 days per month.

          4. Has taken nitroglycerine-containing medications within 60 days prior to study
             enrollment.

          5. Failed more than 3 clinical studies of effective migraine prevention medications due
             to uncontrolled migraines.

        Additional exclusion criteria in protocol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>74 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>W. M. Mulleners</last_name>
    <role>Principal Investigator</role>
    <affiliation>Canisius-Wilhelmina Zeikenhuis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mediwest Research Centre Oy</name>
      <address>
        <city>Koskenalantie 16</city>
        <state>Seinajoki</state>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Turun Headache Center, Ltd. (Turun Paansarkykeskus Oy)</name>
      <address>
        <city>Brahenkatu 11D, Turku</city>
        <state>Turku</state>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suomen Terveystalo Jyvaskyla</name>
      <address>
        <city>Jyvaskyla</city>
        <state>Vainonkatu 30</state>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Headache Center, Tammertutka</name>
      <address>
        <city>Hameenkatu 18 6th Floor, Tampere</city>
        <zip>33200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Porin Laakerikeskus</name>
      <address>
        <city>Itsenalsyydenk. 33, Pori</city>
        <zip>28100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Isala Kliniek</name>
      <address>
        <city>Groot Wezenland 20</city>
        <state>Zwolle</state>
        <zip>8000</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ziekenhuisgroep Twente, Afdeling Neurolgie , Locatie Streekziekenhuis Midden Twente</name>
      <address>
        <city>Geerdinksweg 141, Hengelo</city>
        <zip>7555</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Anna Hospital, Bogardeind 2</name>
      <address>
        <city>Geldrop</city>
        <zip>5664</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canisius Wilhelmina Hospital, Afdeling C02.04</name>
      <address>
        <city>Weg door Jonkerbos 100 SZ Nimegen</city>
        <zip>6532</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Fowey River Practice; Rawlings Lane</name>
      <address>
        <city>Fowey</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Alverton Practice, 7 Alverton Terrace</name>
      <address>
        <city>Penzance</city>
        <state>Cornwall</state>
        <zip>TR18 4JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saltash Health Centre</name>
      <address>
        <city>Saltash</city>
        <state>Cornwall</state>
        <zip>PL 12 6DI</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Staploe Medical Centre</name>
      <address>
        <city>Soham</city>
        <state>Eky</state>
        <zip>CB7 5JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stonehill Medical Centre, Piggot st.</name>
      <address>
        <city>Farnworth BL4 9QZ Bolton</city>
        <state>Lancashire</state>
        <zip>BL4 9QZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanwell Road Surgery, 25 Stanwell Road</name>
      <address>
        <city>Ashford</city>
        <state>Middlesex</state>
        <zip>TW15 3EA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Circle Practice/Belmont Health Centre</name>
      <address>
        <city>Harrow</city>
        <state>Middlesex</state>
        <zip>HA3 7LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Woolwell Medical Centre</name>
      <address>
        <city>Devon</city>
        <state>Plymouth</state>
        <zip>PL6 7TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical Centre, Kingston ave</name>
      <address>
        <city>East Horsley</city>
        <state>Surrey</state>
        <zip>KT24 6QT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albany House Medical Centre, 3 Queen St.</name>
      <address>
        <city>Wellingborough</city>
        <zip>NN8 4RW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
    <country>Netherlands</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 31, 2006</study_first_submitted>
  <study_first_submitted_qc>January 31, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 2, 2006</study_first_posted>
  <last_update_submitted>February 6, 2008</last_update_submitted>
  <last_update_submitted_qc>February 6, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2008</last_update_posted>
  <responsible_party>
    <name_title>John A. McLane</name_title>
    <organization>Ariston Pharmaceuticals, Inc</organization>
  </responsible_party>
  <keyword>Migraine</keyword>
  <keyword>Migraine prophylaxis</keyword>
  <keyword>Migraine prevention</keyword>
  <keyword>Chronic migraine treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
    <mesh_term>Migraine with Aura</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

